Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D Tap, Hans Gelderblom, Emanuela Palmerini, Jayesh Desai, Sebastian Bauer, Jean-Yves Blay, Thierry Alcindor, Kristen Ganjoo, Javier Martin-Broto, Christopher W Ryan, David M Thomas, Charles Peterfy, John H Healey, Michiel van de Sande, Heather L Gelhorn, Dale E Shuster, Qiang Wang, Antoine Yver, Henry H Hsu, Paul S Lin Show all
The Lancet | ELSEVIER SCIENCE INC | Published : 2019
Awarded by National Institutes of Health National Cancer Institute
We thank the patients who volunteered to participate in this study; their family members and caregivers; the study centre staff members who cared for the patients; the sponsor staff involved in data collection and analyses; Stefano Ferrari (IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy) for his contributions to the study; and Heather Nyce (SciStrategy Communications) for medical writing assistance in the development of the manuscript. Research and manuscript support was provided by Daiichi Sankyo (Tokyo, Japan). All research at Memorial Sloan Kettering is supported in part by a grant from the National Institutes of Health National Cancer Institute (#P30 CA008748).